Getting your Trinity Audio player ready...





Pressure BioSciences’ Partner Veterans Service Team Increases Existing Purchase Order by 10X

for Bottles of UltraShear Nano-CBD Topical Spray, Effective Immediately

We feel that these shares have bottomed at historical bargain levels. Shorts have driven these shares to their current oversold condition . We expect a rebound as the markets bottom and rebound. Speculators can place these shares on their BUY LIST immediately


Pressure BioSciences’ Partner Veterans Service Team Increases Existing Purchase Order by 10X for Bottles of UltraShear Nano-CBD Topical Spray, Effective Immediately

PBIO Acknowledges Rapidly Emerging Demand Potential for UltraShear Nanoemulsions for Transformation of Diverse Major Markets, with Recently Announced Readiness and Scaling Plans

SOUTH EASTON, MA / ACCCESSWIRE / September 22, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBIO” or “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty process development and testing services to the global nutraceuticals, cosmeceuticals, food/beverage, biotherapeutics, and other industries, and the Veterans Service Team (“VST”) (, a self-funded, 501(c)3 non-profit company dedicated to the support and wellness of active duty and former members of all branches of the US Military and US Coast Guard, today announced that VST has increased its existing purchase order with PBIO by 10-fold (from 500 to 5,000 bottles), effective immediately.

PBIO’s Ultra Shear TechnologyTM (UltraShearTM or USTTM) platform allows oil-soluble active molecules like CBD to be prepared into nanoemulsions of vanishingly tiny oil droplets in water that ensure rapid absorption and unparalleled bioavailability of the CBD (or other active ingredients) into the water-based biochemistry of human bodies. The PBIO-VST partnership offers VST membership exclusive access to custom-designed, hemp-derived, UltraShear-processed nanoemulsions of CBD oil in water (“Nano-CBD”), providing unparalleled speed of action and reliable dosage delivery. VST is initially launching their uniquely differentiated UltraShear Nano-CBD Topical Spray, with plans for its sister product, UltraShear Nano-CBD Oral Spray, to quickly follow.

In a June 2023 press release announcing the new, five-year partnership between VST and PBIO, Mr. Howard Zall, COO of VST, explained that a leading-quality CBD product with world class speed and completeness of dose delivery and effectiveness had been the most important new offering that VST was targeting in 2023, to help address and manage a diversity of critical needs for their members. Mr. Zall stated they had determined that PBIO’s UltraShear Technology was the world’s leading platform for developing highly effective nanoemulsions of CBD in either a topical or oral spray. They were (and are) excited to partner with PBIO, to soon introduce to their membership the first product to emerge from this collaboration: a revolutionary, all-natural, preservative-free, highly potent, UltraShear nanoemulsified CBD topical spray.

Mr. John B. Hollister, Director of Marketing and Sales, commented: “Yesterday we announced the successful expansion of internal capabilities to ensure the fulfillment of existing orders, starting in early October. Today we are announcing a 10-fold increase in the number of bottles of one of these existing orders. Although this request is a significant increase, it is important to note that our VST partner has advised us that this may be the “tip of the iceberg”, and that PBIO needs to be ready to respond to such large orders in the near future, both often and quickly.”

Mr. Richard T. Schumacher, President and CEO of PBIO, concluded: “As stated in our June announcement, VST believes their membership will exceed two million of the nearly 18 million active-duty personnel and veterans within five years. PBIO and VST estimate that PBIO’s revenue from this relationship will significantly grow year-over-year, from initial annual revenue of about $1.5M to as much as $15M in the fifth year of the agreement. These projections are for Nano-CBD products sales only (both topical and oral), which the companies believe will be generated from sales of up to 50,000 spray bottles in Year 1 to approximately 500,000 spray bottles in Year 5. PBIO investors and VST members can expect to hear much more about additional UltraShear processed products developed and offered through VST in the months ahead.”

About Veterans Service Team (VST)

The VST mission is to serve the roughly 18 million current members and veterans of the US Armed Services and Coast Guard with education, support services, and a potent collection of diverse, carefully selected health and wellness products. VST is in the early stages of building membership, through which they expect to increase VST to over 2 million members in the next five years. VST’s founder, Captain George Ackerson, is an exceptional individual with a strong, diverse background. As a seasoned business professional and former Military Officer, he brings a wealth of experience to the table. Notably, Captain Ackerson served in Vietnam as a Special Ops Scout Helicopter Pilot, demonstrating his bravery and commitment to service. Captain Ackerson’s passion lies in supporting fellow veterans by leveraging his extensive knowledge and expertise. With a deep understanding of health and wellness, he strives to make a meaningful impact and empower others through innovative approaches.

Pressure BioSciences Fulfillment of UltraShear Nano-CBD Orders is Underway; Customer Shipments Begin First Week of October

Further Innovations Announced, with All Systems Go for Fulfilling Current and Future Orders; UltraShear is No Longer Just the Name of a Patented, Revolutionary, One-of-a Kind Nanoemulsification Process, It is Now a Revenue-Generating Machine.

SOUTH EASTON, MA / ACCESSWIRE / September 21, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBIO” or the “Company”), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide nutraceuticals, cosmeceuticals, food and beverage, biotherapeutics, and other industries, today announced that the Company’s initial expansion of its launch-phase manufacturing capacity has been completed, that backorders of reagents and supplies needed for Nano-CBD processing by the Company’s patented UltraShearTM Technology platform (UltraShearTM or USTTM) have been received, and that a review of the Company’s Quality Systems has been completed. The Company will begin fulfilling the orders it has received and announced over the past six weeks, with an expectation that initial shipments of product will begin the week of October 2nd and that new orders will continue to grow throughout the Company’s fourth quarter, and beyond.

The UltraShear process is used to create a Nano-CBD Topical Spray, with uniquely uniform and ultra-low nano-droplet sizes of hemp-derived CBD oil in water, creating a best-in-class, super-fast acting, highly bioavailable, all natural, preservative-free, and highly potent (40 mg/ml) CBD product. CBD has been heavily popularized by researchers and consumers alike for addressing pain, stress, anxiety, sleep disorders and more. PBIO has also recently disclosed the completion of an important preclinical study performed by leading academics, as well as consumer focus group testing in commercial settings, all providing compelling supporting evidence for its revolutionary improvements over conventional CBD edibles and its “best-in-class” nanoemulsion performance. The Company anticipates imminent publication in a scientific peer-reviewed journal of research performed by a leading global cannabis academic research team, highlighting vastly superior absorption and bioavailability achieved by PBIO’s UltraShear Nano-CBD.

Recently, PBIO has announced the achievement of a number of milestones in its Nano-CBD project, including:

  • Second progress report on UltraShear Nano-CBD launch (“Drive to 420”) -five new orders received (Aug 30)
  • Strongly accelerating UltraShear Nano-CBD orders. First five purchase orders received. (Aug 9)
  • Evaluation of the UltraShear process for shelf-life extension coatings on fresh produce. (July 25)
  • Nano-CBD commercial rollout program enters rapid expansion Phase 2. (July 17)
  • Nano-CBD topical spray distribution agreement with leading CA company Crème de Canna. (July 10)
  • Key academic publication further validates PBIO’s UltraShear platform’s impact in clean-label foods. (July 6)
  • Partnership with Somalab International for development of UltraShear-enabled health products. (July 5)
  • PBIO partners with Veterans Service Team to offer exclusive access for VST members to Nano-CBD. (June 13)
  • Commercial availability of Best-in-Class Nano-CBD topical spray with lightning-fast action announced. (May 22)

Mr. John B. Hollister, Director of Marketing and Sales, commented, “We have 10 purchase orders in hand, with an estimated value of up to half a million dollars. We expect to close on an additional 15 orders before the end of 2023, and to have a minimum of 50 orders within a year. The PBIO team has worked hard to expand our capabilities and to acquire the necessary materials and equipment to help ensure that we can begin to fulfill the orders in hand by early October, as well as anticipated new orders as they arrive. We have succeeded in both: our manufacturing capabilities are now ready for prime time and the fulfillment of the initial hundreds of thousands of dollars of orders has begun.”

Mr. Hollister continued: “While we have spent recent weeks focused on closing initial orders, we have also been completing enormous amounts of preparatory work in getting PBIO ready to fulfill current and future production demands and have introduced new innovations in the process. We are particularly pleased to have sourced an innovative spray dispensing bottle format that incorporates a laboratory standard 0.2 micron filter in the air return pathway (air drawn in to replace air expelled during spraying). Starting with our all-natural, preservative-free product design and the effective sterility achieved during UltraShear processing, this innovative filtered spray bottle design helps to protect and maintain product sterility and stability during routine use and complements our prioritization of a green/clean-label consumer-responsive design.”

Mr. Richard T. Schumacher, President and CEO, said: “PBIO has reached the inflection point that we have discussed over recent months. We are not just launching into the fulfilment of the hundreds of thousands of dollars in orders that we have in-hand, but we are also now prepared and ready for fulfillment of the additional orders anticipated throughout the fourth quarter and beyond. While it has been a long and winding road for our team and our shareholders, the good news is that the sun is shining bright on the super-highway opening up ahead of us. UltraShear is no longer just the name of a patented, revolutionary, one-of-a kind nanoemulsification process, it is now a revenue-generating machine!”

Pressure BioSciences Provides Second Progress Report on UltraShear Nano-CBD Launch and Commercialization Program “Drive to 420!”

Additional Five Customers Committed to Distributing PBIO’s Best-in-Class UltraShear Nano-CBD, Representing Nearly 350 Retailers and Over $200K Incremental 2023 Sales

SOUTH EASTON, MA / ACCESSWIRE / August 30, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBIO” or the “Company”), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide biotherapeutics nutraceuticals, cosmeceuticals, food and beverage, and other industries, is committed to providing the market with updates on their launch progress and commercialization program for their revolutionary, best-in-class Nano-CBD product, manufactured with PBIO’s proprietary UltraShear™ technology platform. Since the press release of August 9, the Company has received commitments from an additional five new distributors, initially reflecting expected incremental 2023 revenues of between $200K and $250K. These new distributors consist of both on-line marketers and distributors who supply to their own dispensaries. This group alone represents over 345 dispensaries, and anticipated reorders are expected to significantly increase 2023 revenues beyond the initial purchase quantities.

Mr. John B. Hollister, Director of Marketing and Sales commented, “In launching this best-in-class product, UltraShear Nano-CBD, a long-time advisor noted that a goal of placing and selling our Nano-CBD through 420 separate retailers (on-line or traditional brick and mortar locations) with modest monthly turnover assumptions would achieve annual incremental PBI revenues of $9M+. Thus, was born our “Drive to 420″ commercialization program! The 420 target has particular elegance, reflecting the cultural phenomenon of 4/20 as an informal holiday and rallying point for the celebration and advocacy for legalization of cannabis across diverse application areas. CBD is the principal non-psychotropic ingredient in cannabis and is proliferating in adoption for more medicinal and nutraceutical applications daily.”

Mr. Hollister continued: “With this second group of distributors announced, spanning Massachusetts, Illinois, Indiana and Maine, we are closing in on prospective access to 420 retail outlets within just the first month of launching this revolutionary performing product. It looks like we will need to raise the bar, as the early response to our Drive to 420 program has been fabulous. We are already discussing terms and signing up the next group of distributors across the USA and will update investors again during September!”

Mr. Richard T. Schumacher, President and CEO of PBIO, expanded: “Our team and investors are all relishing our arrival at this pivotal moment in PBIO’s history. We are proud of our journey through the development of three powerful, enabling high-pressure technology platforms and bringing them each to market traction, each with their own important value proposition for the large potential markets that they serve. However, it became clear to us that UltraShear’s transformative impact upon multiple multi-billion dollar markets from nutraceuticals to cosmeceuticals, pharmaceuticals, agrochemicals, food/beverages and more could be truly game-changing, indeed altering the terms of competition for each of them. Speed of action, effective dosage payload delivery, safety, consumer preference for “green” label and preservative-free products are all dramatically impacted by UltraShear.”

Mr. Schumacher concluded: “We correspondingly reoriented PBIO’s strategic priorities over the past 2-3 years, and have dedicated the majority of our resources towards accelerating the development and commercialization of UltraShear. Even before recent pivotal pre-clinical research is published in a peer-reviewed journal, we are already witnessing the excitement of distributors, retailers and consumers in the early adoption and sales ramping of this important new product delivery vehicle for a myriad of oil-soluble active components that are critical nutraceutical, nutrient, health, wellness and beauty product ingredients.”

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB:PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Our products utilize both constant and alternating pressure. Our patented enabling technology platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. We have recently expanded our market opportunities with the acquisition of the BaroFold™ patented technology platform, allowing us to enter the bio-pharma contract services and GMP manufacturing equipment sector. We have also developed the scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Our commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers.

Forward-Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,””could,””would,” “expects,” “plans,” “intends,””anticipates,” “believes,” estimates,””predicts,” “projects,””potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.